​

Adaptimmune Therapeutics (ADAP) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Adaptimmune Therapeutics Revenue Highlights

Latest Revenue (Y)

$178.03M

Latest Revenue (Q)

$7.29M

Main Segment (Y)

Development revenue

Adaptimmune Therapeutics Revenue by Period

Adaptimmune Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$178.03M195.34%
2023-12-31$60.28M122.05%
2022-12-31$27.15M341.50%
2021-12-31$6.15M55.36%
2020-12-31$3.96M252.76%
2019-12-31$1.12M-98.11%
2018-12-31$59.51M57.28%
2017-12-31$37.83M166.47%
2016-12-31$14.20M32.43%
2015-06-30$10.72M1673.22%
2014-06-30$604.63K100.00%
2013-06-30--

Adaptimmune Therapeutics generated $178.03M in revenue during NA 2024, up 195.34% compared to the previous quarter, and up 15867.38% compared to the same period a year ago.

Adaptimmune Therapeutics Revenue by Quarter

DateRevenueChange
2025-03-31$7.29M126.10%
2024-12-31$3.22M-92.12%
2024-09-30$40.90M-68.10%
2024-06-30$128.23M2158.38%
2024-03-31$5.68M2336.82%
2023-12-31$233.01K-96.82%
2023-09-30$7.32M42.67%
2023-06-30$5.13M-89.22%
2023-03-31$47.60M331.64%
2022-12-31$11.03M57.39%
2022-09-30$7.01M26.53%
2022-06-30$5.54M54.91%
2022-03-31$3.58M152.29%
2021-12-31$1.42M17.79%
2021-09-30$1.20M-61.13%
2021-06-30$3.10M613.13%
2021-03-31$434.00K-71.11%
2020-12-31$1.50M25.90%
2020-09-30$1.19M137.65%
2020-06-30$502.00K-34.03%
2020-03-31$761.00K4.53%
2019-12-31$728.00K207.17%
2019-09-30$237.00K50.96%
2019-06-30$157.00K100.00%
2019-03-31--100.00%
2018-12-31$1.48M-96.37%
2018-09-30$40.79M351.34%
2018-06-30$9.04M10.27%
2018-03-31$8.20M91.94%
2017-12-31$4.27M-84.29%
2017-09-30$27.18M672.08%
2017-06-30$3.52M23.24%
2017-03-31$2.86M-66.53%
2016-12-31$8.54M253.31%
2016-09-30$2.42M636.59%
2016-06-30$328.00K-88.76%
2016-03-31$2.92M-25.94%
2015-09-30$3.94M100.00%
2015-03-31--100.00%
2014-12-31$2.27M47.92%
2014-09-30$1.53M-

Adaptimmune Therapeutics generated $7.29M in revenue during Q1 2025, up 126.10% compared to the previous quarter, and up 3126.49% compared to the same period a year ago.

Adaptimmune Therapeutics Revenue Breakdown

Adaptimmune Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21Dec 20
Development revenue$176.80M$60.28M$27.15M$6.15M-
Product revenue, net$1.24M----
Development And Service----$3.96M

Adaptimmune Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: Development revenue (99.31%), and Product revenue, net (0.69%).

Quarterly Revenue by Product

Product/ServiceJun 25Mar 25Dec 24Sep 24Dec 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Product revenue, net$11.08M$4.05M------------------
Development revenue$2.60M$3.24M$135.90M$40.90M$7.55M$5.13M$47.60M$11.03M$7.01M$5.54M$3.58M$1.20M--------
Development And Service------------$3.10M$434.00K$1.50M$1.19M$502.00K$761.00K$728.00K$237.00K

Adaptimmune Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Jun 25: Product revenue, net (81.00%), and Development revenue (19.00%).

Adaptimmune Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ADAPAdaptimmune Therapeutics$178.03M$7.29M
LVTXLAVA Therapeutics$11.98M-
VRCAVerrica Pharmaceuticals$7.57M$12.70M
EYENEyenovia$57.34K$14.72K
RVPHReviva Pharmaceuticals--
PDSBPDS Bio--
NCNANuCana--
IOBTIO Biotech--
MURAMural Oncology--
JSPRJasper Therapeutics--
PSTVPlus Therapeutics-$1.06M

ADAP Revenue FAQ

What is Adaptimmune Therapeutics’s yearly revenue?

Adaptimmune Therapeutics's yearly revenue for 2024 was $178.03M, representing an increase of 195.34% compared to 2023. The company's yearly revenue for 2023 was $60.28M, representing an increase of 122.05% compared to 2022. ADAP's yearly revenue for 2022 was $27.15M, representing an increase of 341.50% compared to 2021.

What is Adaptimmune Therapeutics’s quarterly revenue?

Adaptimmune Therapeutics's quarterly revenue for Q1 2025 was $7.28M, a 126.10% increase from the previous quarter (Q4 2024), and a 28.30% increase year-over-year (Q1 2024). The company's quarterly revenue for Q4 2024 was $3.22M, a -92.12% decrease from the previous quarter (Q3 2024), and a 1282.78% increase year-over-year (Q4 2023). ADAP's quarterly revenue for Q3 2024 was $40.9M, a -68.10% decrease from the previous quarter (Q2 2024), and a 458.83% increase year-over-year (Q3 2023).

What is Adaptimmune Therapeutics’s revenue growth rate?

Adaptimmune Therapeutics's revenue growth rate for the last 3 years (2022-2024) was 555.78%, and for the last 5 years (2020-2024) was 4398.03%.

What are Adaptimmune Therapeutics’s revenue streams?

Adaptimmune Therapeutics's revenue streams in c 24 are Development revenue, and Product revenue, net. Development revenue generated $176.8M in revenue, accounting 99.31% of the company's total revenue, up 193.29% year-over-year. Product revenue, net generated $1.24M in revenue, accounting 0.69% of the company's total revenue

What is Adaptimmune Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Adaptimmune Therapeutics was Development revenue. This segment made a revenue of $176.8M, representing 99.31% of the company's total revenue.